دورية أكاديمية
Leptomeningeal metastases from solid tumors: A SNO and ASCO consensus review on clinical management and future directions.
| العنوان: | Leptomeningeal metastases from solid tumors: A SNO and ASCO consensus review on clinical management and future directions. |
|---|---|
| المؤلفون: | Wilcox JA; Department of Neurology, Brain Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chukwueke UN; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Aizer AA; Department of Radiation Oncology, Brigham and Women's Hospital / Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Bale TA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Brandsma D; Department of Neuro-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Brastianos PK; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Chang S; Division of Neuro-Oncology, Department of Neurosurgery, University of San Francisco California, San Francisco, CA, USA., Daras M; Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA., Forsyth P; Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Garzia L; Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada., Glantz M; Department of Neurosurgery, Penn State College of Medicine, Hershey, PA, USA., Oliva ICG; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kumthekar P; The Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA., Le Rhun E; Departments of Neurology and Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland., Nagpal S; Division of Neuro-Oncology, Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA., O'Brien B; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pentsova E; Department of Neurology, Brain Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lee EQ; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Remsik J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Laboratory for Immunology of Metastatic Ecosystems, Center for Cancer Biology, VIB, Leuven, Belgium.; Department of Oncology, KU Leuven, Leuven, Belgium., Rudà R; Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital, Turin, Italy.; Department of Neurology, Castelfranco Veneto and Treviso Hospitals, Castelfranco Veneto, Italy., Smalley I; Department of Tumor Biology, The Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Taylor MD; Division of Neurosurgery, Department of Surgery, Texas Children's Hospital, Houston, TX, USA Neuro-oncology Research Program, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine., Weller M; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland., Wefel J; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang JT; Department of Radiation Oncology, Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA., Young RJ; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Boire AA; Department of Neurology, Brain Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. |
| مؤلفون مشاركون: | International Leptomeningeal Metastasis Collaborative |
| المصدر: | Neuro-oncology [Neuro Oncol] 2024 Jun 21. Date of Electronic Publication: 2024 Jun 21. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2010- : Oxford : Oxford University Press Original Publication: 1999-<2002> : Charlottesville, VA : Carden Jennings Pub., |
| مستخلص: | Leptomeningeal metastases are increasingly becoming recognized as a treatable, yet generally incurable, complication of advanced cancer. As modern cancer therapeutics have prolonged the lives of patients with metastatic cancer, specifically in patients with parenchymal brain metastases, treatment options and clinical research protocols for patients with leptomeningeal metastases from solid tumors have similarly evolved to improve survival within specific populations. Recent expansion in clinical investigation, early diagnosis, and drug development have given rise to new unanswered questions. These include leptomeningeal metastasis biology and preferred animal modeling, epidemiology in the modern cancer population, ensuring validation and accessibility of newer leptomeningeal metastasis diagnostics, best clinical practices with multi-modality treatment options, clinical trial design and standardization of response assessments, and avenues worthy of further research. An international group of multi-disciplinary experts in the research and management of leptomeningeal metastases, supported by the Society for Neuro-Oncology and American Society of Clinical Oncology, were assembled to reach a consensus opinion on these pressing topics and provide a roadmap for future directions. Our hope is that these recommendations will accelerate collaboration and progress in the field of leptomeningeal metastases and serve as a platform for further discussion and patient advocacy. (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.) |
| فهرسة مساهمة: | Keywords: Leptomeningeal metastases; consensus guideline; intrathecal therapy; leptomeningeal disease; radiation therapy; systemic therapy |
| تواريخ الأحداث: | Date Created: 20240621 Latest Revision: 20240621 |
| رمز التحديث: | 20240621 |
| DOI: | 10.1093/neuonc/noae103 |
| PMID: | 38902944 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1523-5866 |
|---|---|
| DOI: | 10.1093/neuonc/noae103 |